A Phase II, Multicenter, Single-Arm Study OF Atezolizumab In Patients With PD-L1-Positive Locally Advanced Or Metastatic Non-Small Cell Lung Cancer
Active, no longer recruiting
Phase of Trial: Phase II
Latest Information Update: 21 Feb 2018
At a glance
- Drugs Atezolizumab (Primary)
- Indications Non-small cell lung cancer
- Focus Therapeutic Use
- Acronyms BIRCH
- Sponsors Genentech; Roche
- 19 Jan 2018 Planned End Date changed from 1 Dec 2018 to 29 Sep 2018.
- 17 Jan 2018 Results of pooled data from four trials (BIRCH, POPLAR, IMvigor210 and PCD4989g), were published in the Journal of Clinical Oncology.
- 18 Oct 2017 Updated efficacy results presented at the 18th World Conference on Lung Cancer.